Clinical Trial

Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The hypothesis of this pilot trial is that administration of bortezomib will inhibit NHEJ in metastatic TNBC leading at the time of disease progression to metastases that are HR-deficient and sensitive to pembrolizumab and cisplatin therapy. The trial will include in depth analysis of the patients' TNBC genome and phosphoproteome to evaluate HR-proficiency and deficiency, and nuclear proteins that drive NHEJ, before and upon progression with bortezomib therapy.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2020-02-10; most recent amendment 2026-02-10.
Status change: Not Yet Recruiting → Recruiting 2020-10-19
Trial Details
NCT Number NCT04265872
Lead Sponsor Baylor Research Institute
Conditions Breast Cancer
Enrollment 20 participants
Start Date 2020-10-15
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-12